Literature DB >> 8024659

Optic gliomas in neurofibromatosis type 1: role of visual evoked potentials.

K North1, C Cochineas, E Tang, E Fagan.   

Abstract

Optic gliomas occur in 15% of patients with neurofibromatosis type 1 (NF 1) and are a significant cause of morbidity. Of these tumors, 20-30% become symptomatic, usually before age 10 years. Previous studies have suggested that visual evoked potentials (VEPs) are a sensitive method for the detection of asymptomatic optic gliomas. Because routine neuroimaging of children with NF 1 is currently not recommended, the role of pattern-shift VEPs (PS VEPs) as a screening test for optic gliomas was evaluated. PS VEPs were performed on 10 children with NF 1 and optic gliomas and 20 children with NF 1 and normal visual pathways (as defined on MRI). PS VEPs had 90% sensitivity for detecting optic gliomas, with an increase in sensitivity to 100% when hemifield stimulation was used. The specificity of the test was 60%. Four of 20 children without optic gliomas had thickened optic nerves on computed tomography which represented dural ectasia with normal visual pathways on MRI; PS VEPs were normal in these patients. The efficacy of PS VEPs as a routine screen for optic gliomas is limited by the age at which children will cooperate with the test procedure and the high incidence of false-positive results; however, VEPs do provide a useful adjunct to routine clinical ophthalmologic assessment in the detection of optic gliomas in children with NF 1. Abnormal test results provide a stronger indication for neuroimaging. The early detection of optic gliomas allows for close monitoring of tumor progression and earlier intervention prior to significant visual loss.

Entities:  

Mesh:

Year:  1994        PMID: 8024659     DOI: 10.1016/0887-8994(94)90043-4

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  11 in total

1.  Visual pathway glioma: an erratic tumour with therapeutic dilemmas.

Authors:  A Shuper; G Horev; L Kornreich; S Michowiz; R Weitz; R Zaizov; I J Cohen
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

Review 2.  Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

Authors:  Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

Review 3.  Role of visual evoked potentials in the assessment and management of optic pathway gliomas in children.

Authors:  C Van Mierlo; W Spileers; E Legius; I Casteels; C Cassiman
Journal:  Doc Ophthalmol       Date:  2013-07-25       Impact factor: 2.379

Review 4.  Special issues in the management of gliomas in children with neurofibromatosis 1.

Authors:  I F Pollack; J J Mulvihill
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

5.  Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.

Authors:  Patrícia de Freitas Dotto; Adriana Berezovsky; Andrea Maria Cappellano; Nasjla Saba da Silva; Paula Yuri Sacai; Frederico Adolfo B Silva; Arthur Gustavo Fernandes; Daniel Martins Rocha; Solange Rios Salomão
Journal:  Doc Ophthalmol       Date:  2018-05-15       Impact factor: 2.379

6.  Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1.

Authors:  John P Kelly; Avery H Weiss
Journal:  Neuro Oncol       Date:  2013-10-06       Impact factor: 12.300

7.  Electrophysiological monitoring in a patient with an optic nerve glioma.

Authors:  Phillip Moradi; Anthony G Robson; Geoffrey E Rose; Graham E Holder
Journal:  Doc Ophthalmol       Date:  2008-02-27       Impact factor: 2.379

8.  Longitudinal assessment of childhood optic gliomas: relationship between flicker visual evoked potentials and magnetic resonance imaging findings.

Authors:  Benedetto Falsini; Lucia Ziccardi; Ilaria Lazzareschi; Antonio Ruggiero; Luca Placentino; Anna Dickmann; Lucia Liotti; Marco Piccardi; Emilio Balestrazzi; Cesare Colosimo; Concezio Di Rocco; Riccardo Riccardi
Journal:  J Neurooncol       Date:  2008-02-02       Impact factor: 4.130

9.  Visual evoked potentials in children with neurofibromatosis type 1.

Authors:  Alessandro Iannaccone; Richard A McCluney; Vickie R Brewer; Peter H Spiegel; June S Taylor; Natalie C Kerr; Enikö K Pivnick
Journal:  Doc Ophthalmol       Date:  2002-07       Impact factor: 2.379

10.  Functional outcome measures for NF1-associated optic pathway glioma clinical trials.

Authors:  Michael J Fisher; Robert A Avery; Jeffrey C Allen; Simone L Ardern-Holmes; Larissa T Bilaniuk; Rosalie E Ferner; David H Gutmann; Robert Listernick; Staci Martin; Nicole J Ullrich; Grant T Liu
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.